Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

ents.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation alirocumab; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials, such as the ODYSSEY global trial program evaluating alirocumab; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, such as alirocumab, including the impact (if any) of the planned use of the U.S. Food and Drug Administration's Rare Pediatric Disease Priority Review Voucher in connection with the contemplated Biologics License Application submission for alirocumab; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates; the ability
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 6, 2015   University of Maryland (UM) ... today the signing of an exclusive option by Biomecite ... (UMB) to develop diagnostics to detect inflammatory bowel diseases ... (CD). Drs. Florian Fricke and James ... with the University of Maryland School of Medicine,s Institute ...
(Date:5/6/2015)... May 6, 2015 ... specialist, announced today that it has signed an agreement ... PEIX ) for the delivery of an industrial scale ... the consumption of water, energy and emissions ... This project is fully aligned ...
(Date:5/5/2015)... Frederick, MD (PRWEB) May 05, 2015 ... solutions provider released FreezerPro® version 7, the latest major ... management software., Upgrade is a ... Revamped UI succeeds in enhancing users experience, while also ... overall performance, reduces system requirements , Download ...
(Date:5/5/2015)...  23andMe, Inc., the leading personal genetics company, today ... in collaboration with Pfizer Inc. The companies aim ... commonly known as lupus, into the study to help ... also in collaboration with the Lupus Research Institute, and ... Approximately 1.5 million people in the U.S. suffer ...
Breaking Biology Technology:Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3Whitefox Signs Agreement With Pacific Ethanol Inc. 2RURO Releases version 7 of FreezerPro® software 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3
... 2011 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: ... that the United States Patent and Trademark Office (USPTO) has ... D and Fam3C are Biomarkers for Alzheimer,s Disease."  The patent ... as combinations that include these biomarkers. "This patent ...
... and HONG KONG, May 25, 2011 SuperNova ... human and non-human health applications, today announced it ... Valley Association of Startup Entrepreneurs (SVASE) annual Launch: ... campus on Tuesday, June 7, 2011 at 1:15 ...
... Otonomy, Inc., a clinical stage biopharmaceutical company ... the inner and middle ear, today announced the ... operations officer.  Mr. Wroblewski brings the company broad ... supply chain management, packaging and quality assurance.  At ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Alzheimer Patent 2Vermillion Announces Notice of Allowance for Alzheimer Patent 3SuperNova Diagnostics® Selected to Present at Launch: Silicon Valley 2011 2Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 2Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 3
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... translations of a basic research discovery into a promising ... be discussed publicly for the first time by the ... Dec. 14, at the American Society for Cell Biology ... is Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), a rare, ...
... Practice as well as sleep may help birds learn ... during sleep helps young songbirds to develop the vocal ... have found. Sleep is well known to ... processes studied in humans, including acquiring complex skills such ...
... Search & Match,the leading provider of high-performance search ... joined the company as Product Marketing Manager. , ... years of product and marketing management,experience to the ... high-tech products and solutions worldwide. He has deep ...
Cached Biology News:In just 5 years, gene discovery to clinical trial of potential treatment 2In just 5 years, gene discovery to clinical trial of potential treatment 3In just 5 years, gene discovery to clinical trial of potential treatment 4Practice as well as sleep may help birds learn new songs 2Practice as well as sleep may help birds learn new songs 3
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Biology Products: